Zobrazeno 1 - 4
of 4
pro vyhledávání: '"translocation t(6"'
Autor:
Andrea Ceglédi, Zoltán Csukly, Mónika Fekete, András Kozma, Zsuzsanna Szemlaky, Hajnalka Andrikovics, Gábor Mikala
Publikováno v:
Pathology and Oncology Research, Vol 29 (2023)
Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation. However, the efficacy of venetoclax in myeloma patients wit
Externí odkaz:
https://doaj.org/article/f1942aab14334e64bc29fb8dba190576
Autor:
Gemma E. Logan, David M. Markovitz, Edgar Jost, M.J. Percy, Pia Verena Schmidt, Nirit Mor-Vaknin, Ken I. Mills, Till Braunschweig, Ferdinand Kappes
Publikováno v:
Blood cells, molecules, & diseases : BCMD 54(1), 123-131 (2015). doi:10.1016/j.bcmd.2014.07.009
Logan, G E, Mor-Vaknin, N, Braunschweig, T, Jost, E, Schmidt, P V, Markovitz, D M, Mills, K I, Kappes, F & Percy, M J 2015, ' DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML) ', Blood Cells, Molecules and Diseases, vol. 54, no. 1, pp. 123-131 . https://doi.org/10.1016/j.bcmd.2014.07.009
Logan, G E, Mor-Vaknin, N, Braunschweig, T, Jost, E, Schmidt, P V, Markovitz, D M, Mills, K I, Kappes, F & Percy, M J 2015, ' DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML) ', Blood Cells, Molecules and Diseases, vol. 54, no. 1, pp. 123-131 . https://doi.org/10.1016/j.bcmd.2014.07.009
Blood cells, molecules, & diseases : BCMD 54(1), 123-131 (2015). doi:10.1016/j.bcmd.2014.07.009
Published by Elsevier, San Diego, Ca.
Published by Elsevier, San Diego, Ca.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb3785e2d99b0d5d92cf594350726dbd
https://pubmed.ncbi.nlm.nih.gov/25128083
https://pubmed.ncbi.nlm.nih.gov/25128083
Publikováno v:
Journal of leukemia (Los Angeles, Calif.)
Translocation t(6;9) is a rare cytogenetic abnormality found in fewer than 5% of pediatric and adult cases of acute myelogenous leukemia (AML). The outcomes of t(6;9) AML are generally poor, with low five-year overall survival and increased risk for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9fc669e218673939965df6c25575e6e
https://doi.org/10.4172/2329-6917.1000167
https://doi.org/10.4172/2329-6917.1000167
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.